Tumor‐bearing mice were randomized for treatment with the RANKL inhibitors RANK‐Fc or denosumab (the latter used only in the STG139‐M model as it expresses hRANKL) or mock (control). This evidence concerns the gene TNFRSF11A and neoplasm.